FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) reports that the clinical study that was initiated in August with its proprietary formulation of oral calcitonin has now been successfully completed. All of the subjects achieved a biological response and the study met the desired goals for blood levels and variability.
The tablets used in the study utilized an improved solid dosage form of Unigene's Enteripep® oral delivery technology for which a patent application has been filed. The study measured the blood levels of an established marker of bone resorption in eighteen post-menopausal women.
